Business Context and Reporting Period
This Form 8-K was filed by Cerecor Inc. (trading symbol: CERC) on February 4, 2020, reporting events occurring on February 3, 2020. The company is an emerging growth company incorporated in Delaware. Note: The request metadata references "Avalo Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Cerecor Inc.
Key Financial Metrics and Transaction Details
- Transaction Type: Entry into a Material Definitive Agreement for a private placement of common stock.
- Shares Sold: 1,306,282 shares of common stock.
- Purchase Price: $3.98 per share.
- Gross Proceeds: Approximately $5.2 million.
- Placement Agent Fees: Approximately $110,000 paid to Wedbush Securities Inc., plus reimbursement of out-of-pocket expenses.
- Net Proceeds: Approximately $5 million.
- Use of Proceeds: General corporate purposes, working capital, clinical development of pipeline assets, and payment of transaction costs related to the merger with Aevi Genomic Medicine.
Material Changes and Unusual Items
The filing reports a material capital raise event. Funds associated with Armistice Capital, LLC, a significant shareholder, participated in the offering. The transaction is expected to close on or about February 6, 2020, subject to customary closing conditions. The offering was conducted pursuant to an effective shelf registration statement (Form S-3) filed in September 2019.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or forward-looking projections regarding revenue or earnings. Management commentary is limited to the intended use of proceeds to support clinical development and merger-related costs. The filing includes standard risk disclosures regarding the representations and warranties in the Purchase Agreement, noting they are for risk allocation between parties and may not reflect materiality standards viewed by stockholders.
Key Facts for Investor Verification
- Verify the closing of the offering on or about February 6, 2020, and the actual receipt of net proceeds.
- Confirm the dilution impact of the issuance of 1,306,282 new shares on existing shareholders.
- Review the final prospectus supplement to be filed with the SEC for updated terms.
- Monitor the progress of the merger with Aevi Genomic Medicine and the allocation of funds toward its transaction costs.
- Check subsequent filings for any changes in the company's cash position or clinical development milestones funded by this capital.